Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Figure created with Biorender

👉 *In vitro* method for the prognosis and/or for predicting mortality risk in patients suffering from Coronavirus infection.

CLINICAL NEED / NEED

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a coronavirus strain responsible for a respiratory illness. In February 2020, the WHO declared the COVID-19 outbreak a public health emergency of international concern. However, **there are no sensitive and specific tests** able to correlate the mortality risk with the presence of viremia and/or the degree of viral replication.

SOLUTION

Our group has developed a **new *in vitro* prognosis test for COVID-19** that allows the rapid identification of patients with a higher mortality risk and need of hospitalization.

COMPETITIVE ADVANTAGE

Highly sensitive and specific tests are crucial for the **early identification** and selection of patients with a higher mortality risk. Respiratory secretion sampling does not offer a solution to this problem. Our test quantifying COVID-19 antigen in plasma offers a sensitive and specific prediction of mortality.

INTELLECTUAL PROPERTY

European patent (EP20383140) application was submitted in December 2020. Currently in national phase in Europe. Applicants: HCB and FRCB-IDIBAPS.

DEVELOPMENT

Critically and non-critically COVID-19 patients have been screened in a multicentric study in Spain.

GRANTS AND AWARDS

CIBERES – UCICOVID 2020

LOOKING FOR...

Partners (Diagnostic, CROs) for **licenses agreement.**

THE TEAM

Clínic Barcelona

IDIBAPS

Dr. Antoni Torres

Professor of Medicine (Pulmonology) University of Barcelona

Group leader in " Applied research in infectious respiratory diseases and critically ill patients" research area at IDIBAPS.

October 2024